SAGE Therapeutics (SAGE) Tops Q1 EPS by 9c

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.52), $0.09 better than the analyst estimate of ($1.61).

Financial Guidance: Sage expects that its existing cash, cash equivalents and marketable securities will fund its anticipated level of operations, based on its current operating plans, into the second quarter of 2018.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Creatd files Form S-1 and reports Q1 2026 financial results
• John Wiley & Sons, Inc. (WLYB) Tops Q4 EPS by 12c; Offers Outlook